CADL - NASDAQ
Candel Therapeutics, Inc.
$8.80
+4.5%Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
At a Glance
Live SnapshotCandel Therapeutics, Inc. Management Team
Dr. William Garrett Nichols M.D., M.S.
Chief Medical Officer
Ms. Ileen B. Winick
Chief People Officer
Ms. Susan Stewart J.D., L.L.M.
Chief Regulatory Officer
Dr. Francesca Barone M.D., Ph.D.
Chief Scientific Officer
Compensation
$726,222
Dr. Seshu Tyagarajan Ph.D.
Chief Technical & Development Officer
Compensation
$613,231
Mr. Charles Schoch
Interim Chief Financial Officer, Principal Accounting Officer, Treasurer & Secretary
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
President, Chief Executive Officer & Director
Compensation
$1,449,222
Candel Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $9.93M and sold $2K worth of CADL shares, resulting in $9.92M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
550.5K
3.00M
0
0.00
+3.0M
+$3.00M
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
1.5M
6.93M
1.7K
2.21K
+6.9M
+$6.92M
Top Buyers
Manning Paul B
Director
$8.07M
Martell Christopher
Director
$590K
Papa Joseph C
Director
$370K
Schoch Charles
Officer: Chief Financial Officer
$262K
Tak Paul Peter
Director, Officer: Chief Executive Officer
$200K
Top Sellers
Nichols William Garrett
Officer: Chief Medical Officer
$2K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $9.92M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
CADL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 23, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 17, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | May 30, 2024 | June 26, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 23, 2023 | June 28, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | September 02, 2022 | October 13, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.